NorthWest Biotherapeutics Inc (NWBO)

[longfellow95]

Umibe.
It is highly unlikely that the subjects in this trial have had tumor samples tested for transcriptional subclass. Such testing requires facilities only normally found in a specialised research lab.
One suspects that all the tumor material obtained from surgeries would have been used to create the lysate.

I hope, as indeed NWBO surely does, that the unblinded data will show benefit across the board, albeit to a greater degree with methylated. Certainly the TOP 100 data would suggest that this might be the case, with only 8% having the combination of all three main positive prognostic indicators.